High prevalence of CLL coupled with its high mortality rate, demonstrates the unmet market need for better therapeutics.
Chronic lymphocytic leukemia (CLL) is a most common type of leukemia found in adults. It is a kind of malignancy characterized by production of abnormal white blood cells in the bone marrow. Symptoms include, swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Although CLL is rarely seen in children and people under age 40, it is more prevalent in geriatric population. Moreover, causes of CLL are largely unknown and it is more severe than acute leukemia. The prevalence of CLL is high in males than females. Although, the incidence of this disorder is higher in white population than Asian populations, the precise cause for this cannot be explained.
Click To Continue Reading on Chronic Lymphocytic Leukemia Therapeutics Market
The diagnosis of CLL includes Blood Cell Count and Examination, Bone Marrow Examination for patients followed by treatment. The treatment includes single or combination drug therapy, targeted therapies, monoclonal antibody therapies, white blood cell (neutrophil) growth factors. In addition to this, there are radiation therapy and splenectomy which are rarely used for the treatment.
According to the American Cancer Society (ACS) estimates, around 20,110 new cases of chronic lymphocytic leukemia and 4,660 deaths from CLL is expected in year 2017 in U.S. Furthermore, high prevalence of CLL in geriatric population is expected to increase demand for chronic lymphocytic leukemia therapeutics. According to the United Nations data, in 2015, around 901 million people in the world were over 60 years of age and this number is expected to reach 1.4 billion by 2030 and to 2.1 billion by 2050.
Furthermore, increasing number of incidences of comorbidities, especially among geriatric population and launch of new pipeline drugs are major factors contributing to growth of the chronic lymphocytic leukemia therapeutics market. For instance, on December 8, 2015, Bendeka injection—manufactured under the collaboration of Teva Pharmaceuticals Industries Ltd. and Eagle Pharmaceuticals Inc. acquired approval from FDA for the treatment of patients with CLL and indolent B-cell non-Hodgkin lymphoma (NHL) — progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
On the basis of region, the chronic lymphocytic leukemia therapeutics market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America accounted for the largest market share in 2016 due to the presence of breakthrough pipeline drugs. For instance, the drug Acalabrutinib—manufactured by Acerta Pharma BV—is under phase 2 clinical trial for the treatment of CLL and small lymphocytic lymphoma (SLL) and the study is expected to complete in January 2019
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2049
Key Vendors:
F. Hoffmann-La Roche Ltd, Novartis International AG, GlaxoSmithKline Pharmaceuticals Limited, Celgene Corporation, Genmab A/S, Abbvie Inc. Teva Pharmaceutical Industries Ltd., Biogen Idec, AstraZeneca plc, Arno Therapeutics, Genzyme Corporation, Gilead Sciences INC., and others.
Contact Us:
Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1–206–701–6702Email: sales@coherentmarketinsights.com
Visit our news Website: https://www.coherenttimes.org/
Aspergillosis Treatment Market Opportunity Analysis, 2018-2026
Patent expiration of branded products and drug resistance to antifungal medications are the factors restraining growth of the market.
Measles Mumps and Rubella (MMR) Vaccines Market Opportunity Analysis, 2018 – 2026
Vaccine manufacturers are focusing on partnering with organizations such WHO, UNICEF, and GAVI Alliance to improve their vaccination programs, in order to reach the maximum population to offer vaccines.
PoC Platform & Technology Market to Surpass US$ 45.4 Billion by 2025
The global POC platform & technology market was valued at US$ 21,370.3 Million in 2016 and is expected to exhibit a robust CAGR of 8.9% over the forecast period (2017 – 2025).
